The German company Sartorius AG did well with money for the whole year 2025. They kept making money and growing their business even though the world market was still getting back on its feet slowly. On 3 February 2026 Sartorius AG shared some numbers for the whole year. These numbers show that Sartorius AG made a lot money from sales and were more profitable than the year before. This is a deal because other companies, in the same industry were still having a tough time. Sartorius AG kept doing even with these problems.

For the year 2025 Sartorius said they made about 3.5 billion euros from sales. This is a jump of 7.6 percent from the year before. The reason for this increase is that people really wanted the things Sartorius makes for bioprocessing. They make a lot of money from selling things that people need to buy again. These things also have prices, which helps Sartorius make more money.

People were not spending a lot of money on equipment and tools, for laboratories. It looks like things are getting a little better for those products.

The results for 2025 had one thing that really stood out which was the EBITDA margin. This margin went up by 1.7 percentage points to 29.7 percent. This shows that the company is doing a job of running its operations and making more money in all areas.

Because things are going in a direction Sartorius was able to make some of its main financial numbers look better. The equity ratio is now at 39.8 percent. The net debt, to underlying EBITDA ratio went down to 3.55. This means the company is doing a job of managing its money and debt.

Dr. Michael Grosse, the CEO of Sartorius AG said that the year 2025 was an one for Sartorius AG. He explained that Sartorius AG did a job of selling things and making money, which is what they wanted to do. Dr. Michael Grosse was happy with how things went. He said that both parts of the Sartorius AG business helped make this happen.

Dr. Michael Grosse noted that Sartorius AG benefited from people buying things from them like they used to. Sartorius AG also did a job of coming up with new ideas for life science applications. Additionally Sartorius AG was careful, with how they spent money, which helped them a lot.

The Bioprocess Solutions Division is really important, to the company because it brings in the money. This division is doing well and sales have gone up a lot. The Bioprocess Solutions Division helps people make biopharmaceuticals, which’s a big market that is getting bigger all the time. The other division, Lab Products & Services Division is smaller. It had a tough time.. The Lab Products & Services Division started to do better in the second half of the year. This helped the company as a whole do better. The Bioprocess Solutions Division and the Lab Products & Services Division together made the company stronger.

Sartorius also put a lot of money into its infrastructure. The company spent around €442 million on its research and production facilities. This included places like Germany, France and South Korea. By doing this Sartorius is getting ready for growth and it wants to be able to respond quickly to what its local markets need. Sartorius is making a move to help Sartorius expand and be more responsive, to its local markets.

Looking ahead to 2026, management forecasts continued profitable growth, underpinned by strong fundamentals in the biopharma market, ongoing innovation, and a diversified portfolio. With a solid balance sheet and high-margin recurring revenues, Sartorius is positioning itself for further expansion even as the broader life-science landscape evolves.